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Introduction {#sec001}
============

Ovarian cancer (OC) it is the most lethal gynecologic malignancy, though it represents only 3% of female cancers worldwide. Its unfavorable prognosis related to a high percentage of late-stage diagnosis ranks OC to the fourth place among the most common cancer-related cause of death in female population \[[@pone.0127711.ref001]\]. Its incidence in the Czech Republic is 23/100,000 individuals and mortality amounts to 15/100,000 individuals \[[@pone.0127711.ref002]\].

The most important risk factor is a family OC history. It has been supposed that hereditary predisposition accounts for at least 10% of OC cases \[[@pone.0127711.ref003]\]. Therefore, the identification of woman carrying the pathogenic mutations in OC-susceptibility genes is an important task enabling tailored OC prevention in high-risk population. The majority of hereditary OC (HOC) cases are also associated with an increased risk of breast cancer (BC) and the most frequent pathogenic mutations in hereditary breast and/or ovarian (HBOC) cancer families affect the *BRCA1* gene and to a lesser extent also *BRCA2* \[[@pone.0127711.ref004]\]. Both genes play an important role in the repair of DNA double-strand breaks (DDSB). Recently, additional genes were described as associated with HOC, among them the *RAD51* paralogs *RAD51C* and *RAD51D*.

Both genes code for proteins involved in genome stability maintenance and they participate in the homologous recombination-mediated DDSB repair \[[@pone.0127711.ref005],[@pone.0127711.ref006]\]. Initial studies reported the *RAD51C* gene (MIM:602774) as another Fanconi anemia (FA) gene designated as *FANCO* because its biallelic germline mutations were found in a patient with FA-like phenotype corresponding to complementation group O \[[@pone.0127711.ref007]\]. The pioneering work of Meindl et al. showed that *RAD51C* is an OC susceptibility gene with a mutation frequency of 1.3% in HBOC patients \[[@pone.0127711.ref008]\]. Since then, further studies have proved the role of the *RAD51C* gene in OC development in up to 2.5% of high-risk HBOC families \[[@pone.0127711.ref009],[@pone.0127711.ref010],[@pone.0127711.ref011],[@pone.0127711.ref012]\] including rare large genomic rearrangements \[[@pone.0127711.ref013]\].

A study by Loveday et al. reported that germline mutations in the *RAD51D* gene (MIM:602954) confer susceptibility to OC in 0.9% of HBOC families (predominantly with more than one case of OC) and estimated the relative risk (RR) at 6.3 for OC and 1.32 for BC \[[@pone.0127711.ref014]\]. Several other studies have confirmed its role in OC susceptibility \[[@pone.0127711.ref015],[@pone.0127711.ref016],[@pone.0127711.ref017],[@pone.0127711.ref018]\].

While individually rare, together all the moderate-penetrance genes can contribute to a significant proportion of OC risk; however, their frequencies vary in different populations \[[@pone.0127711.ref019]\]. The aim of our study was to determine the frequency of germline mutations in *RAD51C* and *RAD51D* among high-risk OC Czech patients negatively tested for *BRCA1* and *BRCA2* mutations.

Methods {#sec002}
=======

Patients {#sec003}
--------

We analyzed 171 DNA samples (obtained from peripheral blood) from *BRCA1* and *BRCA2* negative OC patients collected at our institute between 2000 and 2013. They belonged to either a familial group (N = 62) or a group without family cancer history (N = 109; [Table 1](#pone.0127711.t001){ref-type="table"}) \[[@pone.0127711.ref020]\]. The control group consisted of anonymized DNA samples obtained from 1,226 individuals including 756 non-cancer individuals and 470 blood donors, as described previously \[[@pone.0127711.ref021],[@pone.0127711.ref022]\].

10.1371/journal.pone.0127711.t001

###### Criteria for the enrollment of high-risk *BRCA1*- and *BRCA2*-negative individuals in this study and number of identified mutations in each group.

![](pone.0127711.t001){#pone.0127711.t001g}

  Inclusion criteria:                                                                                                  Patients (N)   *RAD51C* mut (N)   *RAD51D* mut (N)
  --------------------------------------------------- ---------------------------------------------------------------- -------------- ------------------ ------------------
  **Familial cases (N = 62)**                                                                                                                            
                                                      **HBOC families**:                                                                                 
                                                      \- *probands with OC only*                                       41             1                  \(1\)
                                                      \- *probands with both OC and BC*                                9              \-                 \-
                                                      **HOC families** (OC ≥ 2)                                        12             \-                 \-
  **Cases without family cancer history (N = 109)**                                                                                                      
                                                      **Tumor duplicity** (OC and BC)                                  22             \-                 \-
                                                      **OC** diagnosed **at \< 60 y/o or high-grade adenocarcinoma**   87             1 (2)              3
  **Total**                                                                                                                                              
                                                                                                                       **171**        **2 (2)**          **3 (1)**

BC---breast cancer; HBOC---hereditary breast and ovarian cancer; HOC---hereditary ovarian cancer; OC---ovarian cancer; y/o---years old. Number of rare missense variants are in brackets.

All patients and controls were of Central European descent of Czech origin from the Prague region. The study was approved by the Ethical Committee of the General University Hospital in Prague and all participants gave their written informed consent with the use of stored DNA/RNA samples for research purposes.

Mutation analysis {#sec004}
-----------------

All individual coding exons (with intron-exon boundaries) separated by large intronic regions in the *RAD51C* gene were PCR-amplified (primers are listed in [S1 Table](#pone.0127711.s001){ref-type="supplementary-material"}) and analyzed by a high resolution melting (HRM) analysis on the Light Cycler 480 (Roche) using an HOT FirePol EvaGreen HRM Mix (Solis BioDyne) according to the manufacturer's instructions.

Variants in samples with an aberrant melting profile were confirmed by direct sequencing from separate PCR reactions using the BigDye v3.1 on ABI3130 (Applied Biosystems).

All coding exons (including intron-exon boundaries) that form four exonic clusters of the *RAD51D* gene were amplified by PCR and analyzed by direct sequencing (PCR and sequencing primers are listed in [S1 Table](#pone.0127711.s001){ref-type="supplementary-material"}).

All exons with the identified mutations were screened in 1,226 control samples by an HRM analysis and variant samples were confirmed by sequencing.

Detection of large genomic rearrangements (LGRs) {#sec005}
------------------------------------------------

The P260-A1 Kit was used for a multiplex ligation-dependent probe amplification (MLPA) analysis in *RAD51C* according to the manufacturer's protocol. The amplified products were separated on ABI3130 and analyzed by the MRC Coffalyser software (MRC Holland). The MLPA kit for *RAD51D* analysis was not available from any supplier at the time of the analysis.

cDNA analysis {#sec006}
-------------

In order to determine the effect of intronic variant c.1026+5_1026+7delGTA flanking to intron-exon boundary in *RAD51C* we performed a cDNA-based analysis. The total RNA isolated from venous blood was reverse transcribed into the cDNA using SuperScript III reverse transcriptase (Life Technologies) following the manufacturer's protocol. PCR fragment spanning the involved region was amplified (primers are in [S1 Table](#pone.0127711.s001){ref-type="supplementary-material"}). PCR product containing wild-type and aberrant fragments was sequenced in order to characterize aberrant splicing variant.

*In silico* analysis {#sec007}
--------------------

The pathogenicity of missense variants was assessed using the SIFT, PolyPhen, Align GVGD, and CADD score tools as described previously \[[@pone.0127711.ref021],[@pone.0127711.ref022]\]. Frequencies of identified variants were ascertained in NHLBI Exome Sequencing Project (ESP; <https://esp.gs.washington.edu/drupal/>) and 1000 Genomes (<http://www.1000genomes.org/>) databases.

Results {#sec008}
=======

Pathogenic mutations leading to truncation of protein products were identified in five out of 171 (3%) high-risk OC patients, two (1.2%) in *RAD51C* and three (1.8%) in *RAD51D* ([Table 2](#pone.0127711.t002){ref-type="table"}). Two pathogenic alterations were novel. No LGR was found in the *RAD51C* gene, but we could not exclude a presence of LGRs in the *RAD51D* gene that was not analyzed because MLPA kit was unavailable in the time of the analysis. None of the identified alterations was found in the 1,226 non-cancer controls. The age at diagnosis and the family history of cancers in the mutations' carriers are shown in [Table 2](#pone.0127711.t002){ref-type="table"}.

10.1371/journal.pone.0127711.t002

###### Mutations identified in the *RAD51C* and *RAD51D* genes in analyzed high-risk patients.

![](pone.0127711.t002){#pone.0127711.t002g}

  Patient No.                        Exon   cDNA change                                               Protein change   OC/other cancers; (age at diagnosis)   Histology                                   Grade        Stage   Cancer in family; (age at diagnosis)
  ---------------------------------- ------ --------------------------------------------------------- ---------------- -------------------------------------- ------------------------------------------- ------------ ------- -------------------------------------------------------------------
  ***RAD51C***                                                                                                                                                                                                                 
  ***-- truncating mutations***                                                                                                                                                                                                
  218                                2      c.379_380insG[^**+**^](#t002fn001){ref-type="table-fn"}   p.P127Rfs\*28    OC (25)                                mucinous adenocarcinoma                     G3           IC      MS-OC (56), FM-BC (60)
  1273                               8+     c.1026+5_1026+7delGTA                                     p.R322Sfs\*22    OC (27), Endometrial (34)              serous adenocarcinoma                       low-grade            MF-Leukemia (65), FF-Gastric ca (68)
  ***-- rare missense mutations***                                                                                                                                                                                             
  1418                               4      c.641G\>A[^**+**^](#t002fn001){ref-type="table-fn"}       p.R214H          OC (28), Colon ca (28)                 serous cystadenoma, borderline malignancy   ---          IIIC    negative
  1607                               7      c.947A\>G[^**+**^](#t002fn001){ref-type="table-fn"}       p.H316R          OC (55), BC (69), Lung ca (72)         n.a.                                        n.a.         n.a.    negative
  ***RAD51D***                                                                                                                                                                                                                 
  ***-- truncating mutations***                                                                                                                                                                                                
  142                                8      c.694C\>T                                                 p.R232\*         OC (37)                                serous adenocarcinoma                       high-grade   IIIC    negative
  2115                               8      c.694C\>T                                                 p.R232\*         OC (43)                                serous adenocarcinoma                       high-grade   IIIC    negative
  1119                               9      c.879delG[^**+**^](#t002fn001){ref-type="table-fn"}       p.C294Vfs\*16    OC (66)                                n.a.                                        n.a.         n.a.    D-Thyroid ca (44) & Endometrial ca (44)
  ***-- rare missense mutation***                                                                                                                                                                                              
  107                                7      c.629C\>T                                                 p.A210V          OC (33)                                adenocarcinoma                              n.a.         IIIA    FM-BC (n.a.), FS1-BC (56), FS2-Colon ca (47), FF-Prostate ca (72)

^**+**^---novel variants;

B---brother; BC---breast cancer; D---daughter; F---father; FF---father's father; FM---father's mother; FS---father's sister; M---mother; MF---mother's father; n.a.---not available; OC---ovarian cancer.

Note: NG_023199, NM_058216, and NP_478123 reference sequences were used for the *RAD51C* gene and reference sequences NG_031858, NM_002878, and NP_002869 were used for the *RAD51D* gene.

A novel c.379_380insG (p.P127Rfs\*28) variant in *RAD51C* was found in a young OC patient who died 12 months after a diagnosis of mucinous adenocarcinoma. Another *RAD51C* truncating variant was a splice-site alteration, c.1026+5_1026+7delGTA, identified in a patient who developed endometrial carcinoma seven years after a diagnosis of ovarian serous adenocarcinoma. The pathogenic potential of this alteration was demonstrated by the cDNA analysis that revealed aberrant exon 8 skipping, that resulted in frame-shift and premature termination of translation product (p.R322Sfs\*22; [Fig 1](#pone.0127711.g001){ref-type="fig"}). This variant was previously reported once in a control and a patient, respectively, by Loveday *et al*. and in a study by Golmard *et al*. \[[@pone.0127711.ref010],[@pone.0127711.ref011]\].

![cDNA analysis of patient No.1273 uncovered with an intronic variant c.1026+5_1026+7delGTA causing RAD51C out-of-frame exon 8 skipping.\
The electrophoresis (left) of PCR products amplified with primers located in exon 5 and 3' UTR sequence ([S1 Table](#pone.0127711.s001){ref-type="supplementary-material"}) shows two products in a patient No.1273 compared to a wild-type control (C) sample. Sequencing chromatogram of the patient's PCR product shows the presence of aberrantly spliced mRNA with exon 8 skipping.](pone.0127711.g001){#pone.0127711.g001}

The only truncating mutation described recurrently in our study was c.694C\>T (p.R232\*) in *RAD51D*, found in two unrelated young OC patients with serous adenocarcinoma and no family cancer history. The earlier diagnosed patient died of OC dissemination 10 years after the diagnosis. This variant was previously described in Spanish and American HBOC patients \[[@pone.0127711.ref018],[@pone.0127711.ref016]\]. A novel *RAD51D* mutation, c.879delG (p.C294Vfs\*16), was found in an OC patient with a daughter suffering from BC and OC duplicity.

Besides the truncating variants, we found three rare missense variants ([Table 2](#pone.0127711.t002){ref-type="table"}). The c.641G\>A (p.R214H) mutation in *RAD51C* was recently identified in a BC female of African origin \[[@pone.0127711.ref012]\] and described as a low risk variant based on her family history that is in accord with software predictions. The second rare missense variant c.947A\>G (p.H316R) was novel; however, both these alterations in *RAD51C* were predicted as non-pathogenic. The only rare variant- c.629C\>T (p.A210V)---in *RAD51D* was described previously \[[@pone.0127711.ref018]\] and was predicted as pathogenic ([Table 2](#pone.0127711.t002){ref-type="table"}).

Other detected sequence variants presented in a dbSNP (<http://www.ncbi.nlm.nih.gov/snp/>) or HGMD (<https://portal.biobase-international.com/hgmd/pro/start.php>) databases as polymorphisms are listed in [S3 Table](#pone.0127711.s003){ref-type="supplementary-material"}.

Discussion {#sec009}
==========

We identified germline truncating mutations in the *RAD51C* and *RAD51D* genes in 1.2% and 1.8% of analyzed high-risk individuals, respectively, which is consistent with previous studies \[[@pone.0127711.ref023],[@pone.0127711.ref024]\]. Our study provides further evidence that both genes confer a limited but clinically remarkable proportion of OC susceptibility.

First studies reported deleterious truncating mutations in the *RAD51C* and *RAD51D* genes predominantly in HBOC families with two or more OC cases \[[@pone.0127711.ref008],[@pone.0127711.ref014]\]. However, we found the majority (four out of five clearly deleterious mutations; [Table 2](#pone.0127711.t002){ref-type="table"}) in a subgroup of 109 *BRCA1* and *BRCA2* negative OC patients without BC or OC family history. This is in agreement with later studies which identified *RAD51C* and *RAD51D* mutations in an unselected population of OC patients \[[@pone.0127711.ref025],[@pone.0127711.ref016]\]. These results suggest that comprehensive genetic testing of the *RAD51C* and *RAD51D* genes in OC patients should not be limited only to high-risk OC patients with an apparent family history, and an analysis of all OC patients should be considered irrespectively to the family cancer history and age of onset \[[@pone.0127711.ref026]\].

The mean ages of OC onset for women with *RAD51C* and *RAD51D* mutations published in previous studies were 60 years for *RAD51C* (reviewed in \[[@pone.0127711.ref023]\]) and 56.6 years for *RAD51D* ([S4 Table](#pone.0127711.s004){ref-type="supplementary-material"}). Sopik *et al*. proposed the preventive surgery to be delayed until after natural menopause. Nevertheless, in our study the mean ages of OC onset in carriers of truncating variants were 26.0 years for *RAD51C* (25 and 27 years, respectively) and 48.7 years for *RAD51D* (37, 43, and 66 years, respectively). While a small number of mutation carriers might influence this observation, we suppose that the fact that four of five carriers of pathogenic mutations in the *RAD51C* and *RAD51D* genes were premenopausal women younger than 45 years might be of clinical importance. Hence, further studies of carriers in both genes are necessary to estimate the clinical recommendations for risk-reducing bilateral salpingo-oophorectomy (RR-BSO) and until then, the earliest onset of OC in the family should be taken into account. Recently, Baker et al. reported RR-BSO in a 39 years old female BC patient carrying *RAD51D* mutation from family with multiple BC (but no OC) cases \[[@pone.0127711.ref024]\].

In our study, only one proband, carrying the pathogenic *RAD51C* mutation, displayed family cancer history that included OC and BC cases. Since previous studies reported no increased risk of BC for the carriers, later studies described few *RAD51C* and *RAD51D* truncating mutations in BC only families \[[@pone.0127711.ref013],[@pone.0127711.ref027],[@pone.0127711.ref028],[@pone.0127711.ref018],[@pone.0127711.ref024]\]. Although these mutations seem to be very rare in BC patients, they are probably responsible for certain BC predisposition. The pedigrees of mutation carriers include other cancer cases (endometrial, leukemia, thyroid), whose association with the mutations should be further analyzed in detail.

We also identified three rare missense alterations in both genes ([Table 2](#pone.0127711.t002){ref-type="table"}, [S2 Table](#pone.0127711.s002){ref-type="supplementary-material"}). Only the c.629C\>T, p.A210V rare missense variant in the *RAD51D* gene was predicted to be deleterious consistently in all used software prediction tools. However, its pathogenicity cannot be confirmed without further segregation and/or functional analyses. Unfortunately, we were not able to perform a co-segregation analysis in other family relatives.

The penetrance for mutations in moderate penetrance genes is not easy to estimate \[[@pone.0127711.ref029]\]. Initially, Meindl et al. reported a complete segregation of *RAD51C* mutations in HBOC families \[[@pone.0127711.ref008]\]. Further studies estimated the relative risk (RR) of OC for mutation carriers in *RAD51C* (RR = 5.9) and *RAD51D* (RR = 6.3) \[[@pone.0127711.ref010],[@pone.0127711.ref014]\]. Pelttari *et al*. discovered an odds ratio (OR) for Finnish founder mutations in each gene in an unselected population to be 6.3 and 7.1, respectively \[[@pone.0127711.ref030],[@pone.0127711.ref015]\]. These data suggest that the OC risk exceeds the threshold for moderate penetrance genes in *RAD51C* and *RAD51D* mutations carriers and both genes have clinical significance for diagnostic testing and preventive steps for the carriers involving both OC and BC management. Further studies and meta-analyses of published data from various populations worldwide are required to estimate the penetrance in *RAD51C* and *RAD51D* mutation carriers convincingly.

The clinical utility of the identification of *RAD51C* and *RAD51D* mutation carriers is not limited to the prediction of cancer susceptibility only. Both proteins are involved in DNA damage signaling and DDSB repair functionally co-operating with BRCA1 and BRCA2 in processes of homologous recombination (HR). A failure of this repair pathway that could be expected in cancer patients carrying germline pathogenic mutations in *RAD51C* and *RAD51D* sensitizes cancer cells to PARP inhibitors; therefore, patients carrying germline *RAD51C* and *RAD51D* mutations may benefit from this therapy \[[@pone.0127711.ref014]\].

In conclusion, we described novel pathogenic variants in *RAD51C* and *RAD51D* and showed that truncating mutations in both genes could be found in 3% of high-risk Czech OC patients. Our results indicate that the onset of OC in mutation carriers could be younger than expected. We propose that mutation analysis of *RAD51C* and *RAD51D* should be implemented into the comprehensive multi-gene panel testing in high-risk OC patients. However, further studies in various populations can help to improve the estimates of the clinical impact for germline mutation carriers and allow the determination of appropriate screening, follow-up, or prevention strategies.
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